newsfilter
← Latest News
Business Wire·

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

First patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced